Fig 2: Kaplan-Meier survival analysis of the GABPA expression in EC patients by IHC. (a) Effect of the GABPA expression on overall survival in EC patients. (b) Effect of the GABPA expression on disease-free survival in EC patients.

Fig 3: The expression of GABPA in EC patients was analyzed by TCGA database. (a) The transcript level of GABPA in EC tissues and normal endometrial tissues. (b) The expression of GABPA in 23 paired samples (EC tissues and its adjacent normal tissues). (c) The expression of GABPA in different pathological types of EC. (d) The expression of GABPA in two types of EC. (e) The expression of GABPA in different grades of EC. (f) The expression of GABPA in different stages of EC.

Fig 4: Effect of thiazolidinedione on PGC-1a, NRF1, and NRF2 protein levels. (a) The expression of PGC-1a, NRF1, and NRF2 in different groups; ß-actin was used as the loading control. ((b)–(d)) PGC-1a, NRF1, and NRF2 protein levels. “aa” indicates P < 0.01, compared with control group; “b” indicates P < 0.05, compared with MPP+ group; “c” indicates P < 0.05, compared with 0.01 µmol/L 2,4-TZD group; “e” indicates P < 0.05, compared with 1 µmol/L 2,4-TZD group.

Fig 5: The association of GABPA mRNA and its gene methylation was analyzed by TCGA database. (a) The association between the GABPA mRNA expression and its gene methylation. (b) The association between the GABPA mRNA expression and methylated CpG of cg21890848 at the GABPA gene.